Heart drug may reboot immunotherapy for tough breast cancer

NCT ID NCT05741164

Not yet recruiting Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Feb 18, 2026 · Last updated May 16, 2026 · Updated 11 times

Summary

This study tests whether adding a common heart medication (propranolol) to an immunotherapy drug (pembrolizumab) can help shrink tumors in people with advanced triple-negative breast cancer that no longer responds to standard treatment. About 37 adults whose cancer has spread or cannot be removed will receive both drugs. The goal is to see if the combination can restore the immune system's ability to fight the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Emory University Hospital

Atlanta, Georgia, 30322, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.

ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE IV BREAST CANCER AJCC V8 METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA REFRACTORY TRIPLE-NEGATIVE BREAST CARCINOMA UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA